Roche’s exposure to the tariffs is mostly limited to four medicines, three of which it already produces in the U.S., ...

Steminent Biotherapeutics specializes in developing innovative stem cell-based therapeutics that offer new hope for patients ...

An HHS spokesperson said the agency has not yet made a final decision regarding changes to the COVID-19 vaccination ...

In December 2024, the FDA affirmed that the shortage of tirzepatide, marketed as Zepbound for weight loss, had ended, ...

The deal is a blast from the not-too-distant past, when special purpose acquisition companies were an easy way for companies ...

Roche’s Genentech is betting on the Flagship Pioneering–founded company’s discovery platform called DECODE to find new ...

The so-called 'Most Favored Nations' rule would set drug pricing for Medicare in line with the prices paid by other nations, ...

Analysts at BMO Capital Markets expect Summit and Akeso's HARMONi-6 readout to put some pressure on Merck and its blockbuster ...

Just raising the alarm won’t drive action. Use these three steps to turn insights into solutions that leadership can’t ignore ...

Cobenfy’s late-stage flop is BMS’ second high-profile failure in as many weeks. The pharma announced last week that Camzyos ...

Bausch Health has launched a shareholder rights plan—also known as a poison pill defense—designed to prevent any one entity ...